usually type III hyperlipidaemia occurs as a result of an autosomal recessively inherited condition (with variable penetrance)
there is impaired binding of apoE to its receptor
as a result of a mutation of polymorphism of the apo E gene
most common mutation is polymorphism, apo E2 (cysteine is substituted for arginine at position 158) - in 90% of cases of type III hyperlipidaemia patients are homozygous for apo E2
apo E2 homozygosity may not, in itself, cause hyperlipoprolipoproteinaemia (apo E2 homozygosity occurs in about 1% of population) - another condition that results in an additional catabolic effect or overproduction of VLDL may be required. This explains why type III hyperlipidaemia may be associated with conditions such as diabetes or hypothyroidism. Other possible circumstances where type III hyperlipidaemia may develop with apo E2 homozygosity include co-inheritance of a polygenic tendency to hypertriglyceridaemia, high alcohol intake and obesity
other mutations of apo E have been described including an apo E deficiency; also a mutation of the apo E receptor-binding domain have been described which results in type III hyperlipidaemia in heterozygote
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.